Nanobiotix S.A. (NBTX)
NASDAQ: NBTX · Real-Time Price · USD
3.580
-0.030 (-0.83%)
Mar 31, 2025, 12:54 PM EDT - Market open
Nanobiotix Employees
Nanobiotix had 102 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
102
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$443,335
Profits / Employee
-$351,620
Market Cap
169.08M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NBTX News
- 11 hours ago - NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025 - GlobeNewsWire
- 3 days ago - Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC - GlobeNewsWire
- 10 days ago - NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference - GlobeNewsWire
- 13 days ago - NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026 - GlobeNewsWire
- 2 months ago - Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025 - GlobeNewsWire
- 2 months ago - NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer - GlobeNewsWire
- 3 months ago - NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024 - GlobeNewsWire
- 3 months ago - NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer - GlobeNewsWire